Navigation Links
Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma
Date:1/31/2011

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.

The technique, called adoptive immunotherapy, works with the body's immune system to fight cancer. Immune cells, called T lymphocytes, are removed, modified, expanded in large numbers, and given back to the patient. In this case, the process entailed genetically engineering T cell lymphocytes to express receptors directed against a specific antigen on the cancer cell.

"We believe that this approach of adoptive immunotherapy is the most effective means for using the body's immune system to combat cancer," said senior study author Steven A. Rosenberg, MD, PhD, chief of the surgery branch at the National Cancer Institute. "This paper represents the first time that adoptive immunotherapy using genetically modified cells has been successfully used to treat a solid cancer other than melanoma because we are targeting an antigen present on many types of cancer."

The treatment resulted in response rates of 45 percent and 67 percent in malignant melanoma and synovial cell sarcoma patients, respectively.

In earlier trials, Rosenberg and colleagues used adoptive immunotherapy on treatment-resistant patients with metastatic melanoma who had extensive prior therapy. Of 93 patients studied, they found that more than half had measurable responses, including 20 with complete disappearance of all melanoma metastases.

In the current study, 17 patients with treatment-resistant metastatic melanoma or metastatic synovial cell sarcoma received therapy with their own immune T cells. The cells were genetically engineered to express a T cell receptor that recognized the NY-ESO-1 cancer-testes antigen on cancer cells. NY-ESO-1 is expressed in one quarter to one third of common epithelial cancers such as those of the breast, kidney, esophagus and other cancer types, and in about 80 percent of synovial cell sarcoma.

Four of six patients (67 percent) with synovial cell sarcoma and five of 11 (45 percent) melanoma patients had measurable tumor regression. Two of the 11 melanoma patients had complete regression lasting for more than one year. The treatments had minimal toxicity.

"The effectiveness of this treatment in patients with synovial cell sarcoma may mean that this new approach can be used for patients with other cancers as well," Rosenberg said, "And potentially lead to new types of immunotherapy. "

Rosenberg's group recently reported the first example of using adoptive immunotherapy to treat a patient with non-Hodgkin's lymphoma, and continues to explore different ways to genetically modify a patient's immune system to treat cancer. They have also recently published results showing that immune cells could be genetically modified to target and destroy the blood vessels supplying nutrients to tumors in experimental models.


'/>"/>

Contact: Kelly Powell
kelly.powell@asco.org
571-483-1365
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... This week Omega Institute, a premier nonprofit educational retreat center ... October. Omega is offering a record 370 in-person workshops and new online learning ... widespread interest in or need for the knowledge and skills we’ve been cultivating for ...
(Date:5/2/2016)... ... 2016 , ... Dr. Rassouli, dentist in Orange County, CA comments ... research, which was published in the “Journal of the American Geriatrics Society,” more than ... Americans have Alzheimer’s disease. The study found that dental problems may increase the risk ...
(Date:5/2/2016)... , ... May 02, 2016 ... ... report that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants and ... these risks, Novus Medical Detox Center —a leading Florida-based drug treatment ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Sixth Annual Lifestyle Intervention ... Bellagio Hotel in Las Vegas, NV from October 17–19, 2016. The Nevada ... event. , This year’s conference will offer presentations featuring new treatment tracks, ...
(Date:5/2/2016)... ... May 02, 2016 , ... Consultative ... EVP and GM Jim Callandrillo and Duane Reed, VP of business development of ... Business Intelligence and Research Group (PBIRG) General Meeting from May 15-17 at ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
(Date:4/27/2016)... , April 27, 2016 Tie-up ... initiative to save newborns   ... women & newborns in collaboration with Breast Milk Foundation (BMF), ... first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This ... food source for infants and should be available to babies ...
(Date:4/27/2016)... -- Shire plc (LSE: SHP, NASDAQ: ... Officer, will present at the Deutsche Bank 41st Annual Health ... Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... Presentations and Webcasts section of Shire,s Investor website at ... available on this same website for approximately 90 days. ...
Breaking Medicine Technology: